Oscient reiterated by JMP at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities at market outperform and $3 price target. Factive prescriptions for the week ended Dec. 9 were 6,066, of which 5,889 were new prescriptions, which represents 0.91% of the weekly prescriptions for the quinolone class of antibiotics. This compares to 6,065 prescriptions in the previous week. Testim scripts were 4,970 for the week ended Dec. 9, compared with 5,325 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were down 12 cents, or 5.22%, at $2.18 on volume of 820,485 shares versus the three-month running average of 562,494 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.